Fred Alger Management, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Fred Alger Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $2.25 Million - $3.07 Million	-18,558 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $165,381 - $248,270	1,587 Added 9.35%	18,558 $2.75 Million
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $561,141 - $807,423	-6,026 Reduced 26.2%	16,971 $1.85 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $42.4 Million - $70.7 Million	-568,973 Reduced 96.12%	22,997 $2.65 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $14 Million - $17.3 Million	-196,849 Reduced 24.95%	591,970 $47.6 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $24.4 Million - $34.4 Million	371,106 Added 88.84%	788,819 $57.2 Million
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $23.9 Million - $30.7 Million	328,635 Added 368.93%	417,713 $39 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $2.51 Million - $3.53 Million	-40,004 Reduced 30.99%	89,078 $6.5 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $9.09 Million - $12.7 Million	103,829 Added 411.16%	129,082 $11.3 Million
Q2 2018 Jul 19, 2018	BUY	$88.31 - $107.8 $2.23 Million - $2.72 Million	25,253 New	25,253 $2.49 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.